[en] Evidences highlight the role of various CD4+ helper T cells (CD4+ Th) subpopulations in orchestrating the immune responses against cancers. Epigenetics takes an important part in the regulation of CD4+ Th polarization and plasticity. In this review, we described the epigenetic factors that govern CD4+ T cells differentiation and recruitment in the tumor microenvironment and their subsequent involvement in the antitumor immunity. Finally, we discussed how to manipulate tumor reactive CD4+ Th responses by epigenetic drugs to improve anticancer immunotherapy.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Renaude, Elodie ; Université de Liège - ULiège > GIGA > GIGA Cancer - Cancer Signaling ; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, Besançon, France
Kroemer, Marie; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; Department of Pharmacy, University Hospital of Besançon, Besançon, France
Borg, Christophe; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, Besançon, France ; Department of Medical Oncology, University Hospital of Besançon, Besançon, France
Peixoto, Paul ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases ; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; EPIGENEXP Platform, University of Bourgogne Franche-Comté, Besançon, France
Hervouet, Eric; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; EPIGENEXP Platform, University of Bourgogne Franche-Comté, Besançon, France ; DImaCell Platform, University of Bourgogne Franche-Comté, Besançon, France
Loyon, Romain; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Adotévi, Olivier; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, Besançon, France ; Department of Medical Oncology, University Hospital of Besançon, Besançon, France
Language :
English
Title :
Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy.
INSERM - Institut National de la Santé et de la Recherche Médicale EFS - Etablissement Français du Sang Université de Franche-Comté
Funding text :
This work was supported by funding from institutional grants from INSERM, EFS and Univ. Bourgogne Franche-Comté and by the “Ligue Contre le Cancer”, the “Région Bourgogne Franche-Comté (projet d’envergure structurant C-ICI)”and european founds “Programme Interreg France-Suisse 2014-2020 (FEDER) – Projet R-TIC”.
Chraa D, Naim A, Olive D, Badou A. T Lymphocyte Subsets in Cancer Immunity: Friends or Foes. J Leukoc Biol (2019) 105:243–55. doi: 10.1002/JLB.MR0318-097R1
Kim HJ, Cantor H. CD4 T-Cell Subsets and Tumor Immunity: The Helpful and the Not-So-Helpful. Cancer Immunol Res (2014) 2:91–8. doi: 10.1158/2326-6066.CIR-13-0216
Bevan MJ. Helping the CD8+ T-Cell Response. Nat Rev Immunol (2004) 4:595–602. doi: 10.1038/nri1413
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T Cell Help in Cancer Immunology and Immunotherapy. Nat Rev Immunol (2018) 18:635–47. doi: 10.1038/s41577-018-0044-0
Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4+ T Cell Help is Required for the Formation of a Cytolytic CD8+ T Cell Subset That Protects Against Chronic Infection and Cancer. Immunity (2019) 51:1028–42. doi: 10.1016/j.immuni.2019.10.009
Bos R, Sherman LA. CD4+ T-Cell Help in the Tumor Milieu is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes. Cancer Res (2010) 70:8368–77. doi: 10.1158/0008-5472.CAN-10-1322
Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, et al. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity (2017) 47:848–61. doi: 10.1016/j.immuni.2017.10.009
Jabrane-Ferrat N, Faille A, Loiseau P, Poirier O, Charron D, Calvo F. Effect of Gamma Interferon on HLA Class-I and -II Transcription and Protein Expression in Human Breast Adenocarcinoma Cell Lines. Int J Cancer (1990) 45:1169–76. doi: 10.1002/ijc.2910450630
Wang N, Liang H, Zen K. Molecular Mechanisms That Influence the Macrophage M1-M2 Polarization Balance. Front Immunol (2014) 5:614. doi: 10.3389/fimmu.2014.00614
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, et al. Tumour Ischaemia by Interferon-γ Resembles Physiological Blood Vessel Regression. Nature (2017) 545:98–102. doi: 10.1038/nature22311
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The Immune Contexture in Cancer Prognosis and Treatment. Nat Rev Clin Oncol (2017) 14:717–34. doi: 10.1038/nrclinonc.2017.101
Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 Promotes Th2 Responses Through Three Different Mechanisms: Induction of Th2 Cytokine Production, Selective Growth of Th2 Cells and Inhibition of Th1 Cell-Specific Factors. Cell Res (2006) 16:3–10. doi: 10.1038/sj.cr.7310002
Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K. Relative Expression Levels of Th1 and Th2 Cytokine mRNA are Independent Prognostic Factors in Patients With Ovarian Cancer. Oncol Rep (2005) 13:1153–8. doi: 10.3892/or.13.6.1153
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, et al. Intratumor T Helper Type 2 Cell Infiltrate Correlates With Cancer-Associated Fibroblast Thymic Stromal Lymphopoietin Production and Reduced Survival in Pancreatic Cancer. J Exp Med (2011) 208:469–78. doi: 10.1084/jem.20101876
Kitajima M, Ito T, Tumes DJ, Endo Y, Onodera A, Hashimoto K, et al. Memory Type 2 Helper T Cells Induce Long-Lasting Antitumor Immunity by Activating Natural Killer Cells. Cancer Res (2011) 71:4790–8. doi: 10.1158/0008-5472.CAN-10-1572
Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W, et al. Tgf-β Suppresses Type 2 Immunity to Cancer. Nature (2020) 587:115–20. doi: 10.1038/s41586-020-2836-1
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The Immune Contexture in Human Tumours: Impact on Clinical Outcome. Nat Rev Cancer (2012) 12:298–306. doi: 10.1038/nrc3245
Galon J, Bruni D. Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity (2020) 52:55–81. doi: 10.1016/j.immuni.2019.12.018
Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, et al. The Paradox of Th17 Cell Functions in Tumor Immunity. Cell Immunol (2017) 322:15–25. doi: 10.1016/j.cellimm.2017.10.015
Zhang J-P, Yan J, Xu J, Pang X-H, Chen M-S, Li L, et al. Increased Intratumoral IL-17-Producing Cells Correlate With Poor Survival in Hepatocellular Carcinoma Patients. J Hepatol (2009) 50:980–9. doi: 10.1016/j.jhep.2008.12.033
He S, Fei M, Wu Y, Zheng D, Wan D, Wang L, et al. Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients. Int J Mol Sci (2011) 12:7424–37. doi: 10.3390/ijms12117424
Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin Cancer Res (2008) 14:3254–61. doi: 10.1158/1078-0432.CCR-07-5164
Ye Z-J, Zhou Q, Gu Y-Y, Qin S-M, Ma W-L, Xin J-B, et al. Generation and Differentiation of IL-17-Producing CD4+ T Cells in Malignant Pleural Effusion. J Immunol (2010) 185:6348–54. doi: 10.4049/jimmunol.1001728
Alves JJP, De Medeiros Fernandes TAA, De Araújo JMG, Cobucci RNO, Lanza DCF, Bezerra FL, et al. Th17 Response in Patients With Cervical Cancer. Oncol Lett (2018) 16:6215–27. doi: 10.3892/ol.2018.9481
Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is Associated With Poor Prognosis and Promotes Angiogenesis via Stimulating VEGF Production of Cancer Cells in Colorectal Carcinoma. Biochem Biophys Res Commun (2011) 407:348–54. doi: 10.1016/j.bbrc.2011.03.021
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can Promote Tumor Growth Through an IL-6-Stat3 Signaling Pathway. J Exp Med (2009) 206:1457–64. doi: 10.1084/jem.20090207
He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 Promotes Tumor Development Through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells. J Immunol (2010) 184:2281–8. doi: 10.4049/jimmunol.0902574
Song Y, Yang JM. Role of Interleukin (IL)-17 and T-Helper (Th)17 Cells in Cancer. Biochem Biophys Res Commun (2017) 493:1–8. doi: 10.1016/j.bbrc.2017.08.109
Jarnicki AG, Lysaght J, Todryk S, Mills KHG. Suppression of Antitumor Immunity by IL-10 and TGF-Beta-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells. J Immunol (2006) 177:896–904. doi: 10.4049/jimmunol.177.2.896
Barilla RM, Diskin B, Caso RC, Lee KB, Mohan N, Buttar C, et al. Specialized Dendritic Cells Induce Tumor-Promoting IL-10+IL-17+ FOXP3neg Regulatory CD4+ T Cells in Pancreatic Carcinoma. Nat Commun (2019) 10:1424. doi: 10.1038/s41467-019-09416-2
Togashi Y, Shitara K, Nishikawa H. Regulatory T Cells in Cancer Immunosuppression - Implications for Anticancer Therapy. Nat Rev Clin Oncol (2019) 16:356–71. doi: 10.1038/s41571-019-0175-7
Das M, Zhu C, Kuchroo VK. Tim-3 and its Role in Regulating Anti-Tumor Immunity. Immunol Rev (2017) 276:97–111. doi: 10.1111/imr.12520
Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II. J Immunol (2008) 180:5916–26. doi: 10.4049/jimmunol.180.9.5916
Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a Cancer Immunotherapy Target. Immunol Rev (2017) 276:80–96. doi: 10.1111/imr.12519
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol (2009) 27:186–92. doi: 10.1200/JCO.2008.18.7229
Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High Frequency of Tumor-Infiltrating FOXP3+ Regulatory T Cells Predicts Improved Survival in Mismatch Repair-Proficient Colorectal Cancer Patients. Int J Cancer (2010) 126:2635–43. doi: 10.1002/ijc.24989
Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity (2019) 50:1132–48. doi: 10.1016/j.immuni.2019.04.011
Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4⁺ Follicular Helper T Cell Infiltration Predicts Breast Cancer Survival. J Clin Invest (2013) 123:2873–92. doi: 10.1172/JCI67428
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. Immunity (2013) 39:782–95. doi: 10.1016/j.immuni.2013.10.003
Li H, Ilin S, Wang W, Duncan EM, Wysocka J, Allis CD, et al. Molecular Basis for Site-Specific Read-Out of Histone H3k4me3 by the BPTF PHD Finger of NURF. Nature (2006) 442:91–5. doi: 10.1038/nature04802
Li Y, Schulz VP, Deng C, Li G, Shen Y, Tusi BK, et al. Setd1a and NURF Mediate Chromatin Dynamics and Gene Regulation During Erythroid Lineage Commitment and Differentiation. Nucleic Acids Res (2016) 44:7173–88. doi: 10.1093/nar/gkw327
Turner BM. Cellular Memory and the Histone Code. Cell (2002) 111:285–91. doi: 10.1016/s0092-8674(02)01080-2
Meier K, Recillas-Targa F. New Insights on the Role of DNA Methylation From a Global View. Front Biosci (2017) 22:644–68. doi: 10.2741/4508
Kung JTY, Colognori D, Lee JT. Long Noncoding Rnas: Past, Present, and Future. Genetics (2013) 193:651–69. doi: 10.1534/genetics.112.146704
Baguet A, Bix M. Chromatin Landscape Dynamics of the Il4-Il13 Locus During T Helper 1 and 2 Development. Proc Natl Acad Sci USA (2004) 101:11410–5. doi: 10.1073/pnas.0403334101
Morinobu A, Kanno Y, O’Shea JJ. Discrete Roles for Histone Acetylation in Human T Helper 1 Cell-Specific Gene Expression. J Biol Chem (2004) 279:40640–6. doi: 10.1074/jbc.M407576200
Miyatake S, Arai N, Arai K. Chromatin Remodeling and T Helper Subset Differentiation. IUBMB Life (2000) 49:473–8. doi: 10.1080/15216540050166990
Kaneko T, Hosokawa H, Yamashita M, Wang C-R, Hasegawa A, Kimura MY, et al. Chromatin Remodeling at the Th2 Cytokine Gene Loci in Human Type 2 Helper T Cells. Mol Immunol (2007) 44:2249–56. doi: 10.1016/j.molimm.2006.11.004
Zhang F, Boothby M. T Helper Type 1-Specific Brg1 Recruitment and Remodeling of Nucleosomes Positioned at the IFN-Gamma Promoter are Stat4 Dependent. J Exp Med (2006) 203:1493–505. doi: 10.1084/jem.20060066
Chang S, Collins PL, Aune TM. T-Bet Dependent Removal of Sin3A-Histone Deacetylase Complexes at the Ifng Locus Drives Th1 Differentiation. J Immunol (2008) 181:8372–81. doi: 10.4049/jimmunol.181.12.8372
Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T Helper Cell Fate Specified by Kinase-Mediated Interaction of T-Bet With GATA-3. Science (2005) 307:430–3. doi: 10.1126/science.1103336
Lazarevic V, Chen X, Shim J-H, Hwang E-S, Jang E, Bolm AN, et al. Transcription Factor T-Bet Represses TH17 Differentiation by Preventing Runx1-Mediated Activation of the Rorγt Gene. Nat Immunol (2011) 12:96–104. doi: 10.1038/ni.1969
Tumes DJ, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, et al. The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4(+) T Helper Type 1 and Type 2 Cells. Immunity (2013) 39:819–32. doi: 10.1016/j.immuni.2013.09.012
Allan RS, Zueva E, Cammas F, Schreiber HA, Masson V, Belz GT, et al. An Epigenetic Silencing Pathway Controlling T Helper 2 Cell Lineage Commitment. Nature (2012) 487:249–53. doi: 10.1038/nature11173
Zhang Y, Zhang Y, Gu W, Sun B. TH1/TH2 Cell Differentiation and Molecular Signals. Adv Exp Med Biol (2014) 841:15–44. doi: 10.1007/978-94-017-9487-9_2
Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, et al. Interleukin 2 Plays a Central Role in Th2 Differentiation. Proc Natl Acad Sci USA (2004) 101:3880–5. doi: 10.1073/pnas.0400339101
Renaude E, Kroemer M, Loyon R, Binda D, Borg C, Guittaut M, et al. The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment. Int J Mol Sci (2020) 21:1673. doi: 10.3390/ijms21051673
Hasan M, Neumann B, Haupeltshofer S, Stahlke S, Fantini MC, Angstwurm K, et al. Activation of TGF-β-Induced Non-Smad Signaling Pathways During Th17 Differentiation. Immunol Cell Biol (2015) 93:662–72. doi: 10.1038/icb.2015.21
Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis. Immunity (2010) 32:605–15. doi: 10.1016/j.immuni.2010.05.003
Jiang Y, Liu Y, Lu H, Sun S-C, Jin W, Wang X, et al. Epigenetic Activation During T Helper 17 Cell Differentiation Is Mediated by Tripartite Motif Containing 28. Nat Commun (2018) 9:1424. doi: 10.1038/s41467-018-03852-2
Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue. Cancer Res (2009) 69:599–608. doi: 10.1158/0008-5472.CAN-08-2361
Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, et al. Lineage-Specific DNA Methylation in T Cells Correlates With Histone Methylation and Enhancer Activity. Genome Res (2009) 19:1165–74. doi: 10.1101/gr.091470.109
Wang L, Liu Y, Beier UH, Han R, Bhatti TR, Akimova T, et al. Foxp3+ T-Regulatory Cells Require DNA Methyltransferase 1 Expression to Prevent Development of Lethal Autoimmunity. Blood (2013) 121:3631–9. doi: 10.1182/blood-2012-08-451765
Li Q, Zou J, Wang M, Ding X, Chepelev I, Zhou X, et al. Critical Role of Histone Demethylase Jmjd3 in the Regulation of CD4 + T-Cell Differentiation. Nat Commun (2014) 5:5780. doi: 10.1038/ncomms6780
Li F, Zeng Z, Xing S, Gullicksrud JA, Shan Q, Choi J, et al. Ezh2 Programs TFH Differentiation by Integrating Phosphorylation-Dependent Activation of Bcl6 and Polycomb-Dependent Repression of p19Arf. Nat Commun (2018) 9:5452. doi: 10.1038/s41467-018-07853-z
Chen X, Cao G, Wu J, Wang X, Pan Z, Gao J, et al. The Histone Methyltransferase EZH2 Primes the Early Differentiation of Follicular Helper T Cells During Acute Viral Infection. Cell Mol Immunol (2020) 17:247–60. doi: 10.1038/s41423-019-0219-z
Cosmi L, Maggi L, Santarlasci V, Capone M, Cardilicchia E, Frosali F, et al. Identification of a Novel Subset of Human Circulating Memory CD4(+) T Cells That Produce Both IL-17A and IL-4. J Allergy Clin Immunol (2010) 125:222–30. doi: 10.1016/j.jaci.2009.10.012
Obermajer N, Popp FC, Soeder Y, Haarer J, Geissler EK, Schlitt HJ, et al. Conversion of Th17 Into IL-17A(Neg) Regulatory T Cells: A Novel Mechanism in Prolonged Allograft Survival Promoted by Mesenchymal Stem Cell-Supported Minimized Immunosuppressive Therapy. J Immunol (2014) 193:4988–99. doi: 10.4049/jimmunol.1401776
Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM, Hoft DF, et al. Human Tumor-Infiltrating Th17 Cells Have the Capacity to Differentiate Into IFN-γ+ and FOXP3+ T Cells With Potent Suppressive Function. Eur J Immunol (2011) 41:936–51. doi: 10.1002/eji.201040682
Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, et al. Global Mapping of H3k4me3 and H3k27me3 Reveals Specificity and Plasticity in Lineage Fate Determination of Differentiating CD4+ T Cells. Immunity (2009) 30:155–67. doi: 10.1016/j.immuni.2008.12.009
Kanno Y, Vahedi G, Hirahara K, Singleton K, O’Shea JJ. Transcriptional and Epigenetic Control of T Helper Cell Specification: Molecular Mechanisms Underlying Commitment and Plasticity. Annu Rev Immunol (2012) 30:707–31. doi: 10.1146/annurev-immunol-020711-075058
Mukasa R, Balasubramani A, Lee YK, Whitley SK, Weaver BT, Shibata Y, et al. Epigenetic Instability of Cytokine and Transcription Factor Gene Loci Underlies Plasticity of the T Helper 17 Cell Lineage. Immunity (2010) 32:616–27. doi: 10.1016/j.immuni.2010.04.016
Xu T, Stewart KM, Wang X, Liu K, Xie M, Ryu JK, et al. Metabolic Control of TH17 and Induced Treg Cell Balance by an Epigenetic Mechanism. Nature (2017) 548:228–33. doi: 10.1038/nature23475
Shim E-H, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, et al. L-2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer. Cancer Discov (2014) 4:1290–8. doi: 10.1158/2159-8290.CD-13-0696
Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, et al. Histone Methylation Dynamics and Gene Regulation Occur Through the Sensing of One-Carbon Metabolism. Cell Metab (2015) 22:861–73. doi: 10.1016/j.cmet.2015.08.024
Durek P, Nordström K, Gasparoni G, Salhab A, Kressler C, de Almeida M, et al. Epigenomic Profiling of Human CD4+ T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development. Immunity (2016) 45:1148–61. doi: 10.1016/j.immuni.2016.10.022
Waight JD, Takai S, Marelli B, Qin G, Hance KW, Zhang D, et al. Cutting Edge: Epigenetic Regulation of FOXP3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors From Mice and Humans. J Immunol (2015) 194:878–82. doi: 10.4049/jimmunol.1402725
Bam M, Chintala S, Fetcko K, Williamsen BC, Siraj S, Liu S, et al. Genome Wide DNA Methylation Landscape Reveals Glioblastoma’s Influence on Epigenetic Changes in Tumor Infiltrating CD4+ T Cells. Oncotarget (2021) 12:967–81. doi: 10.18632/oncotarget.27955
Borgoni S, Iannello A, Cutrupi S, Allavena P, D’Incalci M, Novelli F, et al. Depletion of Tumor-Associated Macrophages Switches the Epigenetic Profile of Pancreatic Cancer Infiltrating T Cells and Restores Their Anti-Tumor Phenotype. Oncoimmunology (2018) 7:e1393596. doi: 10.1080/2162402X.2017.1393596
Wang D, Quiros J, Mahuron K, Pai C-C, Ranzani V, Young A, et al. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep (2018) 23:3262–74. doi: 10.1016/j.celrep.2018.05.050
Stephen TL, Payne KK, Chaurio RA, Allegrezza MJ, Zhu H, Perez-Sanz J, et al. SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity (2017) 46:51–64. doi: 10.1016/j.immuni.2016.12.015
Sasidharan Nair V, Saleh R, Toor SM, Taha RZ, Ahmed AA, Kurer MA, et al. Epigenetic Regulation of Immune Checkpoints and T Cell Exhaustion Markers in Tumor-Infiltrating T Cells of Colorectal Cancer Patients. Epigenomics (2020) 12:1871–82. doi: 10.2217/epi-2020-0267
Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes Released From Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol Res (2018) 6:1578–92. doi: 10.1158/2326-6066.CIR-17-0479
Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic Silencing of TH1-Type Chemokines Shapes Tumour Immunity and Immunotherapy. Nature (2015) 527:249–53. doi: 10.1038/nature15520
Gonzalez-Cao M, Karachaliou N, Santarpia M, Viteri S, Meyerhans A, Rosell R. Activation of Viral Defense Signaling in Cancer. Ther Adv Med Oncol (2018) 10:1-12. doi: 10.1177/1758835918793105
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell (2015) 162:961–73. doi: 10.1016/j.cell.2015.07.056
Galaine J, Borg C, Godet Y, Adotévi O. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 3:490–502. doi: 10.3390/vaccines3030490
Zanetti M. Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. J Immunol (2015) 194:2049–56. doi: 10.4049/jimmunol.1402669
Tay RE, Richardson EK, Toh HC. Revisiting the Role of CD4+ T Cells in Cancer Immunotherapy—New Insights Into Old Paradigms. Cancer Gene Ther (2021) 28:5–17. doi: 10.1038/s41417-020-0183-x
Muranski P, Restifo NP. Adoptive Immunotherapy of Cancer Using CD4(+) T Cells. Curr Opin Immunol (2009) 21:200–8. doi: 10.1016/j.coi.2009.02.004
Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EKM, et al. Naive Tumor-Specific CD4(+) T Cells Differentiated In Vivo Eradicate Established Melanoma. J Exp Med (2010) 207:651–67. doi: 10.1084/jem.20091921
Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, et al. Glioblastoma-Targeted CD4+ CAR T Cells Mediate Superior Antitumor Activity. JCI Insight (2018) 3. doi: 10.1172/jci.insight.99048
Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, et al. Immune Modulation Underpins the Anti-Cancer Activity of HDAC Inhibitors. Mol Oncol (2021). doi: 10.1002/1878-0261.12953
Ding Z-C, Shi H, Aboelella NS, Fesenkova K, Park E-J, Liu Z, et al. Persistent STAT5 Activation Reprograms the Epigenetic Landscape in CD4+ T Cells to Drive Polyfunctionality and Antitumor Immunity. Sci Immunol (2020) 5. doi: 10.1126/sciimmunol.aba5962
Lesch S, Benmebarek M-R, Cadilha BL, Stoiber S, Subklewe M, Endres S, et al. Determinants of Response and Resistance to CAR T Cell Therapy. Semin Cancer Biol (2020) 65:80–90. doi: 10.1016/j.semcancer.2019.11.004
Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y, et al. Histone Deacetylase Inhibitors Prevent Activation-Induced Cell Death and Promote Anti-Tumor Immunity. Oncogene (2015) 34:5960–70. doi: 10.1038/onc.2015.46
Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-Dose Decitabine Priming Endows CAR T Cells With Enhanced and Persistent Antitumour Potential via Epigenetic Reprogramming. Nat Commun (2021) 12:409. doi: 10.1038/s41467-020-20696-x
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for Established Cancer: Overcoming the Challenges Posed by Immune Evasion. Nat Rev Cancer (2016) 16:219–33. doi: 10.1038/nrc.2016.16
Melssen M, Slingluff CL. Vaccines Targeting Helper T Cells for Cancer Immunotherapy. Curr Opin Immunol (2017) 47:85–92. doi: 10.1016/j.coi.2017.07.004
Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, et al. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clin Cancer Res (2020) 26:704–16. doi: 10.1158/1078-0432.CCR-19-0727
Hirsch L, Zitvogel L, Eggermont A, Marabelle A. PD-Loma: A Cancer Entity With a Shared Sensitivity to the PD-1/PD-L1 Pathway Blockade. Br J Cancer (2019) 120:3–5. doi: 10.1038/s41416-018-0294-4
Ribas A, Wolchok JD. Cancer Immunotherapy Using Checkpoint Blockade. Science (2018) 359:1350–5. doi: 10.1126/science.aar4060
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer. N Engl J Med (2012) 366:2455–65. doi: 10.1056/NEJMoa1200694
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma. J Immunother (2010) 33:828–33. doi: 10.1097/CJI.0b013e3181eec14c
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant Anti-PD-1 Immunotherapy Promotes a Survival Benefit With Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma. Nat Med (2019) 25:477–86. doi: 10.1038/s41591-018-0337-7
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. Neoadjuvant Nivolumab Modifies the Tumor Immune Microenvironment in Resectable Glioblastoma. Nat Med (2019) 25:470–6. doi: 10.1038/s41591-018-0339-5
Sharma P, Allison JP. The Future of Immune Checkpoint Therapy. Science (2015) 348:56–61. doi: 10.1126/science.aaa8172
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic Immunity is Required for Effective Cancer Immunotherapy. Cell (2017) 168:487–502.e15. doi: 10.1016/j.cell.2016.12.022
Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, et al. Functional Systemic CD4 Immunity is Required for Clinical Responses to PD-L1/PD-1 Blockade Therapy. EMBO Mol Med (2019) 11:e10293. doi: 10.15252/emmm.201910293
Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell (2019) 179:1177–1190.e13. doi: 10.1016/j.cell.2019.10.02984
Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, et al. Enhanced Anti-Tumor Efficacy of Checkpoint Inhibitors in Combination With the Histone Deacetylase Inhibitor Belinostat in a Murine Hepatocellular Carcinoma Model. Cancer Immunol Immunother (2019) 68:379–93. doi: 10.1007/s00262-018-2283-0
Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, et al. BET Bromodomain Inhibition Cooperates With PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res (2018) 6:1234–45. doi: 10.1158/2326-6066.CIR-18-0077
Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 Expression in T Cells Improves Efficacy of Anti-CTLA-4 Therapy. J Clin Invest (2018) 128:3813–8. doi: 10.1172/JCI99760
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 Inhibition Activates a Dsrna-STING-Interferon Stress Axis That Potentiates Response to PD-1 Checkpoint Blockade in Prostate Cancer. Nat Cancer (2021) 2:444–56. doi: 10.1038/s43018-021-00185-w
Kim Y-D, Park S-M, Ha HC, Lee AR, Won H, Cha H, et al. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. J Cancer (2020) 11:4059–72. doi: 10.7150/jca.44622
Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, et al. HDAC Inhibition Potentiates Immunotherapy in Triple Negative Breast Cancer. Oncotarget (2017) 8:114156–72. doi: 10.18632/oncotarget.23169
Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase Inhibition Promotes the Generation and Function of Regulatory T Cells. Nat Med (2007) 13:1299–307. doi: 10.1038/nm1652
Wu Q, Nie J, Gao Y, Xu P, Sun Q, Yang J, et al. Reciprocal Regulation of Rorγt Acetylation and Function by P300 and HDAC1. Sci Rep (2015) 5:16355. doi: 10.1038/srep16355
Ho TCS, Chan AHY, Ganesan A. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J Med Chem (2020) 63:12460–84. doi: 10.1021/acs.jmedchem.0c00830
Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. Histone/Protein Deacetylases and T-Cell Immune Responses. Blood (2012) 119:2443–51. doi: 10.1182/blood-2011-10-292003#
